Private importing
Shopping Guide
    Request Form     Request Form for Corporate Service

Product Overview/Feature

  • JP

Code:005391-002

Tsumura Bouiougito[20] : 42bags(for two weeks)

Sale Price:US$25.49

Warehouse Japan1
Manufacturer TSUMURA & CO.
Brand TSUMURA & CO.
JAN Code ---
GS1 ---
Ingredient Code 5200129
Shipping Schedule about 3 weeks after payment

Description

Boiogito is indicated for the relief of the following symptoms of those patients with a white-complexion, soft muscles, a flabby constitution who are easily fatigued, perspire profusely,do not excrete enough urine, and develop edema in the lowerlimbs and swelling and pain of the knee joint:Nephritis, nephrosis, nephropathy of pregnancy, hydrocele testis, obesity, arthritis, carbuncle, furuncle, myositis, edema,dermatosis, hyperhidrosis,and menstrual irregularity

Presentation

2.5g per bag

Feature

Granules

Active Ingredients

7.5 g(3bags for 1day) of TSUMURA Boiogito extract granules contains 3.75 g of a dried extract of the following mixed crude drugs.JP Astragalus Root 5.0 gJP Sinomenium Stem 5.0 gJP Atractylodes Lancea Rhizome 3.0 gJP Jujube 3.0 gJP Glycyrrhiza 1.5 gJP Ginger 1.0 g(JP: The Japanese Pharmacopoeia)

Effect/Efficacy

TJ-20 is indicated for the relief of the following symptoms of those patients with a white-complexion, soft muscles, and a flabby constitution who are easily fatigued, perspire profusely, do not excrete enough urine, and develop edema in the lower limbs and swelling and pain of the knee joint:Nephritis, phrosis,nephropathy of pregnancy, hydrocele testis, obesity, arthritis, carbuncle, furuncle, myositis, edema, dermatosis, hyperhidrosis, and menstrual irregularity.

Usage/Dosage

The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight and symptoms.

Cautions

(1)When TJ-20 is used, the patient’s “SHO” (constitu-tion/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided.
(2)SinceTJ-20 contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc., and if any abnormality is observed, administration should be discontinued.
(3)When TJ-20 is co-adminstered with other Kam-po-preparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs.

Contraindication

Adverse ReactionsTJ-20has not been investigated (drug use investigations, etc.) to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known.
(1)
Clinically significant adverse reactions
1)Interstitial pneumonia: If fever, cough, dyspnea, abnormal pulmonary sound (fine crackle
), etc. are observed, administration of TJ-20 should be dis-continued, and examinations such as X-ray should be performed immediately and appropriate measures such as administration of adrenocortical hormones taken.
Besides, the patient should be advised to discontinue TJ-20 immediately and to make
contact with the physician in the event of fever, cough, dyspnea, etc.
2)Pseudoaldosteronism: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight, etc. may occur. The patient should be carefully monitored (measurement of serum potassium level, etc.), and if any abnormality is observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken.
3)Myopathy: Myopathy may occur as a result of hypokalemia. The patient should be carefully moni-tored, and if any abnormality such as weakness, convulsion/paralysis of limbs,
etc. are observed, administration should be discontinued and appro-priate measures such as administration of potassium preparations should be taken.
4)Hepatic dysfunction ad jaundice: Hepatic dys-function and/or jaundice with elevation of AST(GOT), ALT(GPT), Al-P and -GTP or other symptoms may occur.
The patient should be carefully monitored for abnormal findings.
Administration should be discontinued and appropriate therapeutic measures should be taken, if abnormalities are observed.
(2)Other adverse reaction
Hypersensitivity